Nektar Therapeutics Inc. (NKTR)
Nektar Therapeutics Q1 Earnings Call Highlights
Nektar Therapeutics NASDAQ: NKTR outlined plans to advance its lead regulatory T-cell (Treg) therapy rezpegaldesleukin (REZPEG) into late-stage development, while also reporting first-quarter 2026 financial results and providing updates across its pipeline during its earnings call. Get Nektar Therapeutics alerts:Sign UpREZPEG positioned for phase III in atopic dermatitis President and CEO Howard Robin said the company is “exceptionally proud” of progress over the past year and highlighted phase IIb results in atopic dermatitis and alopecia areata that he said demonstrate clinically meaningful outcomes in two “distinct autoimmune and inflammatory disease settings.
Nektar Q1 Earnings & Revenues Lag Estimates, Pipeline in Focus
NKTR misses Q1 earnings and revenue estimates. Investor focus stays on rezpeg as the company advances late-stage studies in autoimmune diseases.
Nektar Therapeutics (NKTR) Q1 2026 Earnings Call Transcript
Nektar Therapeutics (NKTR) Q1 2026 Earnings Call Transcript
Nektar (NKTR) Moves 18.3% Higher: Will This Strength Last?
Nektar (NKTR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Nektar Therapeutics: 'Strong Buy' On REZPEG POC Established In AD/AA And Late-Stage Development
Nektar Therapeutics: 'Strong Buy' On REZPEG POC Established In AD/AA And Late-Stage Development
Nektar Therapeutics (NKTR) Discusses 52-Week Topline Results From REZOLVE-AA Phase 2b Extension in Severe Alopecia Areata Transcript
Nektar Therapeutics (NKTR) Discusses 52-Week Topline Results From REZOLVE-AA Phase 2b Extension in Severe Alopecia Areata Transcript
Nektar Therapeutics Upcoming AA Data Prediction: Why I Think It Will Be Positive
Nektar Therapeutics is poised for a key catalyst with upcoming REZPEG 52-week maintenance data in Alopecia Areata (AA) before April's end. My base case model projects REZPEG will achieve a probability-adjusted 28% of patients reaching SALT
Nektar Therapeutics (NASDAQ:NKTR) Hits New 1-Year High Following Better-Than-Expected Earnings
Nektar Therapeutics (NASDAQ: NKTR - Get Free Report)'s share price reached a new 52-week high during trading on Friday after the company announced better than expected quarterly earnings. The stock traded as high as $77.00 and last traded at $73.6150, with a volume of 441428 shares changing hands. The stock had previously closed at $70.36. The
Nektar Q4 Earnings & Revenues Trump Estimates, Pipeline in Focus
NKTR Q4 revenues and earnings beat estimates. The company focuses on rezpeg with phase III studies in atopic dermatitis planned for Q2 2026.
Nektar Therapeutics (NKTR) Q4 2025 Earnings Call Transcript
Nektar Therapeutics (NKTR) Q4 2025 Earnings Call Transcript
Nektar Therapeutics (NKTR) Reports Q4 Loss, Tops Revenue Estimates
Nektar Therapeutics (NKTR) came out with a quarterly loss of $1.78 per share versus the Zacks Consensus Estimate of a loss of $2.76. This compares to a loss of $2.25 per share a year ago.
Analysts Estimate Nektar Therapeutics (NKTR) to Report a Decline in Earnings: What to Look Out for
Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
